fda curbs on compounding

US FDA proposes curbs on mass compounding of Novo, Lilly's weight-loss drugs — Photo by Daniel Trylski on Pexels

The Biggest Lie About Prescription Weight Loss

The FDA’s proposed limits will likely raise the cost of compounded GLP-1 weight-loss therapies by up to 30 percent. This change challenges the common belief that compounding offers a consistently low-cost alternative to brand-name injections, especially for patients battling obesity. Medical Disclaimer: This article is for informational purposes only

US FDA proposes curbs on mass compounding of Novo, Lilly's weight-loss drugs — Photo by Phil Evenden on Pexels

fda curbs on compounding

Prescription Weight Loss Crunch: FDA Trims Mass Compounding?

The FDA’s new proposal will raise operating costs for small pharmacies that dispense GLP-1 weight-loss drugs, threatening their ability to stay viable. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. Prescription Weight